Skip to main content

Table 4 Analysis for OS of patients according to hormone receptor status

From: Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases

  HR positive patients HR negative patients
  Univariate Multivariate Univariate Multivariate
Variables Hazard ratio (95% CI) P -value Hazard ratio (95% CI) P -value Hazard ratio (95% CI) P -value Hazard ratio (95% CI) P -value
Age < 40 yr 0.85
(0.60–1.19)
0.344 - - 0.75
(0.47–1.21)
0.237 - -
Postmenopausal state 1.26
0.81–1.94)
0.302 - - - - - -
HER2 positive 1.66
(1.15–2.40)
0.007 1.54
(1.06–2.23)
0.022 0.67
(0.43–1.06)
0.088 - -
DFI* > 2 yr 0.76
(0.54–1.07)
0.12 - - 0.61
(0.38–0.98)
0.040 0.59
(0.36–0.97)
0.036
Initial stage IV 0.76
(0.49–1.19)
0.232 - - 0.96
(0.58–1.59)
0.882 - -
Sum of metastasis sites ≥ 3 1.32
(0.94–1.83)
0.105 - - 1.83
(1.13–2.97)
0.014 1.70
(1.04–2.78)
0.034
Visceral metastasis 1.78
(1.28–2.48)
0.001 1.7
(1.22–2.38)
0.002 - - - -
BP** use 0.67
(0.42–1.19)
0.111 - - 0.56
(0.34–0.91)
0.019 0.50
(0.30–0.83)
0.007
  1. Abbreviations: *, disease free interval; **, bisphosphonate.